San Clemente, CA—Reflow Medical, Inc., a medical device company focused on cardiovascular disease announces that the first patient was successfully treated and enrolled in the DEEPER REVEAL investigational device exemption…
Read More
SAN CLEMENTE, June 28, 2022 — Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent…
San Clemente, CA—Reflow Medical, Inc. announces that it has completed patient enrollment in the DEEPER OUS clinical trial (NCT03807531) for the company’s Temporary Spur Stent System, a novel device that…
SAN CLEMENTE, CA — Reflow Medical, Inc., a California-based medical device company, introduces the Reflow™ Spex™ LP (Low Profile) 0.014 and 0.018-inch reinforced support catheters. The new Spex LP is…
SAN CLEMENTE, CA /October 7, 2020 /Business Wire/ — Reflow Medical, Inc., a California- based medical device company, announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved the…
SAN CLEMENTE, June 10, 2020 — Reflow Medical, Inc., a California-based medical device company, has enrolled the first patients in A Non-Randomized Pilot Study of the Temporary Spur Stent System…
Reflow Medical Announces 510(k) Clearance for an Expanded Indication for the Wingman Catheter to Cross Chronic Total Occlusions (CTOs) in Peripheral Artery Disease SAN CLEMENTE, March 5, 2020 /BUSINESS WIRE/…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical announces that the Temporary Spur Stent System, a novel retrievable stent technology intended for the treatment of below-the-knee (BTK) peripheral artery disease, has been designated…
San Clemente, Calif., July 30th, 2019–(BUSINESS WIRE) — Reflow Medical, Inc. announces that the first patients have been enrolled in its DEEPER OUS clinical trial using the Temporary Spur Stent System. DEEPER…
San Clemente, Calif., April 10th, 2019–(BUSINESS WIRE)– Reflow Medical, Inc. has announced the completion of enrollment in its Wing-IT investigational device exemption trial, a prospective, multicenter, nonrandomized study evaluating the…
Recent Comments